From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism.
The paper reviews the evolution of metabolic polyagonism and the potential of co-agonists like mazdutide but does not provide new clinical data to support its claims.
Where it sits
this study against the rest of the mazdutide (ibi362) corpusSummary and findings
This review discusses the development of engineered GLP-1R/GCGR co-agonists, including mazdutide, and their effects on metabolic parameters. It highlights the importance of GCGR signaling in various metabolic processes. The paper also examines the evolution of proglucagon-derived peptides and their pharmacological implications.
Abstract
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon-Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism-antagonism paradox, receptor-specific causal attribution, and the unresolved limitations of translating molecular pharmacology into durable clinical benefit. Finally, we propose an Activity-Exposure-Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.
Background
The paper addresses the role of oxyntomodulin (OXM) as a proglucagon-derived peptide and its dual receptor agonism. Previous studies have indicated that GCGR signaling influences various metabolic processes, leading to the development of engineered co-agonists. This review is significant as it consolidates knowledge on the evolution and pharmacology of these peptides, which may inform future therapeutic strategies.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
The review synthesizes existing literature on metabolic polyagonism without presenting new data. While it discusses the potential of these peptides, the lack of specific findings limits the ability to draw definitive conclusions about their clinical significance. The review highlights the complexities of translating molecular pharmacology into clinical outcomes, suggesting that further research is necessary.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.